External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home HealthTech IFCC 2023
Roche and Genentech at

IFCC 2023

May 21 - May 25
Rome, Italy
roma.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
May 22 / Roche
Relationship between SARS-CoV-2 viral load, antigen positivity, and infectious titre
This study compares the performance of the Elecsys SARS-CoV-2 Antigen assay with quantitative tests for viral load (RT-PCR) and for infectivity (viral culture) using samples collected in a randomized, controlled trial.
Infectious Disease COVID-19 IFCC-2023

Sign up or login to unlock the full suite of MEDICALLY features
May 21 / Roche
GAAD and GALAD algorithmic scores demonstrate equivalent clinical performance for hepatocellular carcinoma (HCC) surveillance in prospective,multicenter, case-control studies
The GALAD algorithm, combining gender (sex) and age plus serum biomarkers alpha-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) and protein-induced by vitamin K absence-II (PIVKA-II), is a promising aid in the detection of early-stage hepatocellular carcinoma (HCC). This poster presents data from two independent, prospective, case-control studies (STOP-HCC-MCE and STOP-HCC-Panel B). These studies compared the clinical performance of the GALAD and the novel GAAD (gender [sex], age, AFP and PIVKA-II) algorithm for differentiating between early-stage HCC and benign chronic liver disease.
HealthTech Oncology Hepatocellular Carcinoma IFCC-2023

Sign up or login to unlock the full suite of MEDICALLY features
May 21 / Roche
Robustness of cerebrospinal fluid (CSF) amyloid-β 1–42/amyloid-β 1–40 (Aβ42/Aβ40) and phosphorylated tau/amyloid-β 1–42 (pTau/Aβ42) biomarker ratios in classification of amyloid positron emission tomography (PET) positivity in routine clinical use
This study evaluated and compared the robustness of cerebrospinal fluid biomarker ratios, Aβ42/Aβ40 and pTau/Aβ42, in the diagnostic evaluation of Alzheimer’s disease in people with mild cognitive impairment or subjective cognitive decline, with respect to a hypothetical theoretical bias expected in routine clinical use.
HealthTech IFCC-2023

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.